Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2023

Genmab — Maj 2023

Planlagt Fastgjort Låst Flyttet Genmab
490 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • T Offline
    T Offline
    Teller
    wrote on sidst redigeret af
    #113

    Tror bare jeg holder fast lidt endnu... Har ikke solgt i15 år efterhånden, med undtagelse af skattehensyn.

    1 Reply Last reply
    0
    • CupcakeC Offline
      CupcakeC Offline
      Cupcake
      wrote on sidst redigeret af
      #114

      @Troldmanden - langt hen ad vejen er det pharmacy benefit managers (PBM), der bestemmer prisen, idet de tjener mere, jo mere medicinen koster. Patienterne taber. De lever en skjulet tilværelse. https://content.naic.org/cipr-topics/pharmacy-benefit-managers Også god forklarende artikel og video her... https://www.menendez.senate.gov/newsroom/press/sen-menendez-slams-pharmacy-benefits-managers-practices-that-prioritize-profits-and-drive-up-the-cost-of-prescription-drugs-for-patients

      1 Reply Last reply
      0
      • troldmandenT Offline
        troldmandenT Offline
        troldmanden
        wrote on sidst redigeret af
        #115

        Det er jeg heller ikke så overbevist om Nohope. Men hvis og såfremt de får godkendelsen, så bør den vel kunne bryde 3000. Måske over en periode derefter komme i nærheden af ATH.

        1 Reply Last reply
        0
        • troldmandenT Offline
          troldmandenT Offline
          troldmanden
          wrote on sidst redigeret af
          #116

          Cupcake ja det er grotesk. Pharma industrien har dog også ekstrem stor interesse i at det overordnet set er status quo. Hvis de kørte det med auktioner som i DK, så er de tæt på at kunne gå over til en en ren dansk model. Hvor ALLE har adgang til medicin uden meget dyre privat forsikringer

          1 Reply Last reply
          0
          • troldmandenT Offline
            troldmandenT Offline
            troldmanden
            wrote on sidst redigeret af
            #117

            Men det kommer ikke til at ske. For det er jo social staten. Det værste skræmmebillede for R

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #118

              New trial by Hoosier Cancer Research Network (Genmab collaborates) Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
              https://clinicaltrials.gov/ct2/show/NCT05852717

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #119

                nice to see other parties starting trials on your drug before it is even approved...

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #120

                  and another 2 arms for EPCORE NHL-2 - https://clinicaltrials.gov/ct2/history/NCT04663347?A=8&B=9&C=merged#StudyPageTop - Enrollment from 396 to 662 patients

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #121

                    @Legolas breaking the april 18 high of 2947 would confirm your cuphandle.. would target 3450ish if it can stay above that hurdle...

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #122

                      @Bulder can you try sending me a test
                      message here through proinvestor?

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #123

                        i think my main message from the earnings call, if you read between the lines, is that they seem to have much more going on pre-clinical than even i thought

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #124

                          they have done smaller deals we don't know about...

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #125

                            they have interest from big pharma that they don't want to give in to because they want to stick to the 50/50 profit
                            share (and i agree)

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #126

                              he actually said a minimum of 50/50...

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #127

                                we had a discussion on ADC mid april, and it seems we were spot on there; they are fully working on that and also with AbbVie as we suggested...

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #128

                                  Thx E L 🙂

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #129

                                    no problem 😉

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #130

                                      Regarding IRS I also thinks that its must be that Darzalex Faspro could come under price reductions when the IV patents runs out.

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        JKY_VH
                                        wrote on sidst redigeret af
                                        #131

                                        Løntoft "“Investorer kan godt gennemskue, at Genmab investerer massivt i pipelinen, og når de fastholder forventningerne til omkostningerne, så er der nok mere tale om kvartalsvariationer end et bekymrende omkostningspres. Når man dertil lægger, at omkostningerne til fulde er dækket af royalties-indtægter, så vidner det om en robust forretning,” siger Søren Løntoft Hansen, analytiker hos Sydbank."

                                        1 Reply Last reply
                                        0
                                        • D Offline
                                          D Offline
                                          deleted-user
                                          wrote on sidst redigeret af
                                          #132

                                          @Nophope - er du gået tilbage i køb, efter din salgsanbefaling kl. 10:52?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper